Boehringer Ingelheim recently (Annual European Congress of Rheumatology, EULAR-17) announced the results from the pivotal Phase III VOLTAIRE-RA study, confirming that its adalimumab biosimilar candidate BI-695501 have similar efficacy, safety and immunogenicity in moderately-to-severely active Rheumatoid Arthritis patients. VOLTAIRE is a multinational, multicentre, randomised, double-blind, parallel arm study. Approximately, 645 patients (18–80 years) with moderate […]

The post Promising step in rheumatoid arthritis: BI-695501 Demonstrated Clinical equivalence to Adalimumab appeared first on Innoplexus.